View all data FOR FREE!
Create an account today, no credit card required.
| Issue Type | XXXX |
|---|---|
| Country | Belgium |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2029-11-21 |
| Par Value | 1000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 300.00 |
| Coupon | 5.2 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 300 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This UCB SA corporate note has a 5.20% fixed rate coupon paid on a annual basis. It was issued on November 21, 2023 with an issue size of 300.00 million EUR and matures on November 21, 2029 with a last coupon date of November 21, 2028. |
UCB SA, founded in 1928 and headquartered in Brussels, Belgium, is a global biopharmaceutical company focused on the discovery and development of innovative medicines for severe diseases, particularly in neurology and immunology. The company specializes in therapies for conditions such as epilepsy, multiple sclerosis, and Crohn's disease, positioning itself as a key player in the pharmaceutical industry.